Form 4: Kiniksa CEO Sanj Patel Transfers Shares to Family Trusts

Kiniksa Pharmaceuticals' Chairman and CEO, Sanj K. Patel, reported gifting Class A Ordinary Shares to family trusts.

Summary

• Sanj K. Patel, Chairman & CEO of Kiniksa Pharmaceuticals International, plc, reported changes in his beneficial ownership of Class A Ordinary Shares.
• On November 12, 2025, Mr. Patel gifted 111,794 Class A Ordinary Shares from his direct ownership to The Anglia 2013 Revocable Trust.
• On November 13, 2025, The Anglia 2013 Revocable Trust subsequently gifted 60,000 Class A Ordinary Shares to The Patel Family Irrevocable Trust of 2025.
• All reported transactions were executed with a price of $0, indicating they were gifts.
• Following these transactions, Mr. Patel's direct beneficial ownership is 0 shares.
• His indirect beneficial ownership now includes 51,794 shares held by The Anglia 2013 Revocable Trust, 60,000 shares held by The Patel Family Irrevocable Trust of 2025, and 109,795 shares held by The Marina 2016 Irrevocable Trust, totaling 221,589 indirect shares.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a planned transfer of shares as a gift to family trusts, which is a routine personal financial matter for an executive and does not reflect positively or negatively on the company's operational or financial performance.

Positives

• The transactions represent a planned transfer of wealth, likely for estate planning purposes, which is a common practice for executives.
• The shares remain beneficially owned by entities related to the CEO, indicating continued alignment of interests with the company.

Negatives

• No direct negatives for the company or shareholders are apparent from these gift transactions, as they do not involve a sale for cash into the open market.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The gifting of shares by Sanj K. Patel to The Anglia 2013 Revocable Trust and The Patel Family Irrevocable Trust of 2025 constitutes related party transactions, as these trusts are associated with the reporting person, who is the Chairman & CEO.

Stakeholder Impact

• Shareholders: Minimal direct impact. The shares are transferred to trusts associated with the CEO, maintaining his beneficial interest in the company, which can be seen as continued alignment. It is not a sale into the open market.
• Management/Employees: No direct impact.
• Customers/Suppliers/Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 filing details a gift of shares by the CEO to family trusts for estate planning purposes. It does not indicate any change in the company's fundamentals, operational performance, or strategic direction. As such, it provides no new information to warrant a change in investment recommendation based solely on this filing. Investors should continue to hold based on their existing analysis of Kiniksa Pharmaceuticals.

Keywords

Kiniksa Pharmaceuticals, KNSA, Sanj K Patel, Form 4, beneficial ownership, share transfer, gift, family trust, insider transaction, CEO, director